Bridgefront Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-2,381
Closed -$237K 499
2023
Q4
$237K Buy
+2,381
New +$200K 0.18% 237
2023
Q3
Sell
-3,418
Closed -$415K 532
2023
Q2
$415K Buy
+3,418
New +$456K 0.22% 166
2021
Q1
Sell
-3,482
Closed -$364K 829
2020
Q4
$364K Buy
+3,482
New +$352K 0.12% 303

Other funds holding MRNA

Bridgefront Capital's MRNA Position: Q1 2024 in Review

Bridgefront Capital sold out of Moderna (MRNA) in Q1 2024, closing a stake of 2,381 shares — an estimated $237K sold.

Bridgefront Capital first reported a position in MRNA in Q4 2020 and held it in 3 quarters. The position peaked at $415K in Q2 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Bridgefront Capital reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Bridgefront Capital sold 2,381 Moderna shares in Q1 2024, an estimated $237K.
  • Bridgefront Capital first reported a position in Moderna in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's Moderna position peaked at $415K in Q2 2023.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Bridgefront Capital's 13F filing for Q1 2024, filed 15 May 2024.